NYLT
CRL icon

New York Life Trust’s Charles River Laboratories CRL Stock Holding History

New York Life Trust’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,090
Closed -$91K – 222
2016
Q3 		$91K Buy
1,090
+22
+2% +$1.84K 0.45% 82
2016
Q2 		$88K Sell
1,068
-224
-17% -$18.4K 0.43% 85
2016
Q1 		$98K Sell
1,292
-39
-3% -$2.89K 0.42% 81
2015
Q4 		$107K Buy
+1,331
New +$96K 0.46% 79

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

New York Life Trust's CRL Position: Q4 2016 in Review

New York Life Trust sold out of Charles River Laboratories (CRL) in Q4 2016, closing a stake of 1,090 shares — an estimated $91K sold.

New York Life Trust first reported a position in CRL in Q4 2015 and held it in 4 quarters. The position peaked at $107K in Q4 2015. 297 funds tracked by Wall St. Rank hold CRL as of Q4 2016.

  • New York Life Trust reported no remaining Charles River Laboratories position as of Q4 2016 after selling out during the quarter.
  • New York Life Trust sold 1,090 Charles River Laboratories shares in Q4 2016, an estimated $91K.
  • New York Life Trust first reported a position in Charles River Laboratories in Q4 2015 and held it in 4 quarters.
  • New York Life Trust's Charles River Laboratories position peaked at $107K in Q4 2015.
  • 297 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2016.

Based on New York Life Trust's 13F filing for Q4 2016, filed 15 Feb 2017.